S090.F Sutro Biopharma Inc.
- Market cap
- EUR 191M
- P/E
- -
- P/B
- 2.13x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is S090.F undervalued?
Graham numberThe Graham number of Sutro Biopharma Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sutro Biopharma Inc. fundamental analysis
No fundamental analysis for Sutro Biopharma Inc. yet.
Sutro Biopharma Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sutro Biopharma Inc.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carci…
Full company profileSutro Biopharma Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sutro Biopharma Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 61.9M | 67.8M | 154M | 62.0M | 102M | 48.7M |
| Operating Income | -98.5M | -129M | -89.3M | -238M | -105M | -119M |
| EBITDA | - | -108M | -58.0M | -187M | -142M | -107M |
| Net Income | -106M | -119M | -107M | -227M | -191M | -154M |
| EPS | -23 | -21 | -18 | -28 | -22 | -9.29 |
| Balance Sheet | ||||||
| Total Assets | 341M | 407M | 471M | 387M | 174M | 194M |
| Total Liabilities | 88.8M | 190M | 321M | 343M | 306M | 298M |
| Shareholders' Equity | 253M | 217M | 150M | 44.6M | -132M | -103M |
| Cash & Short-term Investments | 30.4M | 47.3M | 69.3M | 190M | 58.1M | 54.3M |
| Cash Flow | ||||||
| Operating Cash Flow | -81.7M | 3.55M | -112M | -192M | -177M | -161M |
| Capital Expenditure | 15.3M | 7.86M | 4.32M | 3.10M | 1.70M | 22.0K |
| Free Cash Flow | -97.0M | -4.31M | -116M | -195M | -179M | -161M |
| Ratios | ||||||
| ROE | -41.8% | -54.9% | -71.4% | -510.0% | - | - |
| ROA | -30.9% | -29.3% | -22.7% | -58.7% | -109.9% | -79.2% |
| Net Profit Margin | -170.6% | -175.9% | -69.5% | -366.6% | -186.5% | -316.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sutro Biopharma Inc. dividends
Sutro Biopharma Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on Dec 3, 2025.
Who owns Sutro Biopharma Inc.
- Insiders 2.26%
- Institutions 97.74%
- Public & others 0.00%
- Shares outstanding 16.6M
- Free float 9.91M
Sutro Biopharma Inc. company profile
- Company name
- Sutro Biopharma Inc.
- Ticker
- S090.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 128
- Fiscal year end
- December
- Address
- 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 881 6500
- Website
- sutrobio.com
About Sutro Biopharma Inc.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma Inc. management
9- Ms. Jane Chung R.Ph.CEO & Director · born 1971
- Mr. Gregory K. Chow BA, CPA, MBAChief Financial Officer · born 1973
- Dr. Hans-Peter Gerber Ph.D.Chief Scientific Officer · born 1964
- Dr. James R. Swartz DSc, Ph.D., Sc.D.Founder
- Mr. Devendra LuharSenior Vice President of Technical Operations
- Ms. Kari E. LeetchSenior VP and Head of People & Culture
- Mr. Jonathan Fawcett DPHIL, MBBSVP & Head of Clinical Development
- Mr. Lucas DonigianSenior Vice President of Business Development
- Ms. Regina ChengVice President & Controller